Ganciclovir ophthalmic gel 0.15%: safety and efficacy of a new treatment for herpes simplex keratitis.

Abstract

BACKGROUND Until the availability of ganciclovir ophthalmic gel in 2009, the only option for treating herpes simplex (HSV) keratitis in the USA has been trifluridine (TFT), a compound with tolerability issues related to its nonselective inhibition of DNA replication in both normal cells and virus-infected cells. Ganciclovir has selective pharmacologic… (More)
DOI: 10.3109/02713683.2012.692846

Topics

Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Statistics

050201520162017
Citations per Year

Citation Velocity: 13

Averaging 13 citations per year over the last 3 years.

Learn more about how we calculate this metric in our FAQ.